Nektar Therapeutics has a targeted portfolio of novel therapeutics that target cytokine pathways and other mechanisms to selectively modulate the immune system and to advance the treatment of cancer, autoimmune disorders, and chronic inflammatory conditions.
Nektar is also engaged in a series of co-development and commercialization collaborations with pharmaceutical industry leaders and emerging biotech companies.
Large B-Cell Lymphoma
Maintenance Bladder Cancer
Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Stage 2 Non-small Cell Lung Cancer Post Chemoradiation
Metastatic Colorectal Cancer or Metastatic Head and Neck Cancer
Relapsed/Refractory Large B Cell Lymphoma
B-Cell Acute Lymphoblastic Leukemia
Systemic Lupus Erythematosus